✦ LIBER ✦

Therapeutics: Drug synergies for imatinib-resistant CML

✍ Scribed by Burgess, Darren J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib mesylate: preferred drug for CM

📂 Article 📅 2003 🏛 Adis International Limited (now part of Wolters Kl ⚖ 140 KB

Dasatinib, nilotinib effective for imati

📂 Article 📅 2006 🏛 Adis International Limited (now part of Wolters Kl ⚖ 121 KB

Novel diagnostics and therapeutics for d

✍ Toosky, M.; Javid, B. 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 393 KB

BCR-ABLT315I transcript disappearance in

✍ Legros, L; Hayette, S; Nicolini, F E; Raynaud, S; Chabane, K; Magaud, J-P; Cassu 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 112 KB

NICE guidance on dasatinib, high-dose im

✍ Scott Goulden; Frances Sutcliffe; Andrew Stevens 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 47 KB

Therapeutic synergy and resensitization

✍ K. Selvendiran; S. Ahmed; A. Dayton; M. Kuppusamy; T. Kálai; K. Hideg; P. Kuppus 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 51 KB